Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

In collaboration with partner HHP, University of Chicago Medicine's food hall at the Center for Care and Discovery (CCD) is celebrating its grand opening this ...

Foremost experts in Movement Disorders, which include the fastest-growing brain disease, will convene to share about and guide the direction of global advancements like artificial intelligence.

We think it's possible that 16 new obesity drugs could launch by 2029, with roughly $70 billion of the GLP-1 market coming from ... pressure drug pricing. Led by Metsera and Hercules (both ...

Obesity is among the world’s most common health conditions, but for years medicine had few effective approaches to offer ...